Tyrosine kinase and immune checkpoints inhibitors in favorable risk metastatic renal cell carcinoma: Trick or treat?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Tyrosine kinase and immune checkpoints inhibitors in favorable risk metastatic renal cell carcinoma: Trick or treat?

Published:2023-09 Issue: Volume:249 Page:108499
ISSN:0163-7258
Container-title:Pharmacology & Therapeutics
language:en
Short-container-title:Pharmacology & Therapeutics

Author:

Catalano Martina,Procopio Giuseppe,Sepe Pierangela,Santoni Matteo,Sessa Francesco,Villari Donata,Nesi Gabriella,Roviello Giandomenico

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference90 articles.

1. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: Extended 4-year follow-up of the phase III CheckMate 214 trial;Albiges;ESMO Open,2020

2. Health-related quality of life analysis from KEYNOTE-426: Pembrolizumab plus Axitinib versus Sunitinib for advanced renal cell carcinoma;Bedke;European Urology,2022

3. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma;Braun;Nature Medicine,2020

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Programmed death receptor (PD-)1/PD-ligand (L)1 in urological cancers : the “all-around warrior” in immunotherapy;Molecular Cancer;2024-09-02

2. First-Line Treatments and Management of Metastatic Renal Cell Carcinoma Patients: An Italian Interdisciplinary Uro-Oncologic Group Algorithm;Cells;2024-06-02

3. Altered expression spectrum and target gene prediction of tRNA-derived small RNAs in clear cell renal cell carcinoma;2024-05-31

4. Banana-shaped survival curves of metastatic renal cell carcinoma treated with first-line immune-combinations, not just a matter of “palateau”;Human Vaccines & Immunotherapeutics;2024-05-17

5. Rationale for immune checkpoint inhibitors plus targeted therapy for advanced renal cell carcinoma;Heliyon;2024-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3